Aeterna Zentaris Inc. (NASDAQ:AEZS)’s share price rose 2.4% during mid-day trading on Monday . The stock traded as high as $3.59 and last traded at $3.45, with a volume of 104,586 shares changing hands. The stock had previously closed at $3.37.

AEZS has been the topic of several recent analyst reports. HC Wainwright restated a “buy” rating and issued a $12.00 target price on shares of Aeterna Zentaris in a report on Sunday, July 10th. Maxim Group restated a “buy” rating and issued a $11.00 target price on shares of Aeterna Zentaris in a report on Tuesday, July 5th. Finally, Canaccord Genuity restated a “buy” rating and issued a $9.00 target price (down previously from $13.00) on shares of Aeterna Zentaris in a report on Monday, April 4th.

The company’s market cap is $34.19 million. The firm’s 50-day moving average is $3.42 and its 200 day moving average is $3.44.

Aeterna Zentaris Inc is a Canada-based specialty biopharmaceutical company engaged in developing treatments in oncology, endocrinology and women’s health. The Company has three wholly owned direct and indirect subsidiaries: AEZS GmbH, based in Frankfurt, Germany, Zentaris IVF GmbH, a direct wholly owned subsidiary of AEZS Germany based in Frankfurt, Germany, and Aeterna Zentaris, Inc Its drug development efforts are focused on two compounds, zoptarelin doxorubicin and Macrilen, which are in clinical development, and on two oncology compounds (an Erk inhibitor and Luteinizing Hormone-Releasing Hormone-disorazol Z product candidates), which are in pre-clinical development.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.